EMEA-002826-PIP01-20-M02

Key facts

Invented name
Veklury
Active substance
remdesivir
Therapeutic area
Infectious diseases
Decision number
P/0338/2021
PIP number
EMEA-002826-PIP01-20-M02
Pharmaceutical form(s)
  • Concentrate for solution for infusion
  • Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
Intravenous use
Contact for public enquiries
Gilead Sciences International Ltd

E-mail: regulatory.pip@gilead.com
Tel. +44 (0)1223 897300

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating
Average
2 ratings
1 rating